While targeted therapies such as B-cell depletion and immune modulation have revolutionized treatment for B-cell malignancies, recent efforts to repurpose these therapies for autoimmune diseases, for example systemic lupus erythematosus (SLE), have gained traction. However, translating oncology-focused B-cell therapies to autoimmune diseases requires addressing fundamental differences in disease pathophysiology, therapeutic goals, and safety profiles.

In this webinar, GemPharmatech’s Dr. Juan Liang will outline key challenges and preclinical evaluation considerations to help you navigate this cross-disciplinary transition.

In our webinar you will learn:

• Review the current state of treatments for B-cell malignancies

• Examine the mechanistic similarities and differences between oncology and autoimmunity

• Understand the unique challenges translating findings in oncology to autoimmune disease

• Examine key considerations for preclinical evaluation

Date:

Tuesday, May 27, 2025

8:00 AM PDT | 10:00 AM CDT | 11:00 AM EDT | 5:00 PM CEST